Summary
- Profile Type
- Business Offer
- POD Reference
- BOGB20250121010
- Term of Validity
- 1 April 2025 - 1 April 2026
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A UK based biotech SME producing bioactive engineered bacterial protein polymer products as alternatives to Extracellular Matrix proteins proteins and growth factors for: large scale cell culture (cultivated meat/cell therapy), tissue models for drug testing, and wound healing. Looking for: partners and beta testers in the various application areas to co-develop and test products. Also looking for partners to help develop a service offering for bespoke solutions for reducing bioprocessing costs
- Full Description
-
This UK company is an early-stage biotech spinout from Newcastle University who specialise in the design and manufacture of proprietary engineered protein polymers.
The company’s patented technology involves genetically encoding peptide motifs from bioactive proteins, such as extracellular matrix (ECM) and growth factors, into an ultra-stable and bioinert bacterial protein scaffold. The resulting engineered protein mimics replace the ECM and growth factors, providing mammalian cells with the signals they require to attach, grow and proliferate, as well as exhibit more complex biological behaviours such as migration and differentiation. The proteins also form polymers that are modular, providing an easy route to making complex multifunctional materials that have not been seen before (e.g. adhesion and growth factor activities in a single material).
The company is led by experienced team of scientists qualified in the field of protein biochemistry to post-doctoral, doctoral, and post graduate levels. These scientists can manufacture the protein inexpensively, scalable and at high yield.
The company possesses a comprehensive catalogue of engineered protein products. Moreover, it is actively pursuing the expansion of its service offerings. This endeavour will involve the deployment of its highly skilled scientific personnel to develop customized reagents, thereby facilitating substantial cost reductions in bioprocessing for its clientele. To
achieve this objective, the company is actively seeking collaborative partnerships with entities located in the Netherlands, France, or Denmark, while also considering other potential geographical regions.
They wish to work with partners who have prior commercial experience in the following targe application areas:
-cultivated meat,
-cell therapy,
-3D models for drug testing
With a view to develop products specific to these target application, as well as providing testing for either our products using their patented technology for these markets the international partner will have expertise in development or developing products in one of these fields: cultivated meat, cell therapy 3D models for drug testing .
Partnership will be through commercial agreement with technical assistance and include licence opportunities - Advantages and Innovations
-
Using this patented technology in targeted application areas such cultivated meat, cell therapy and models for drug testing, will confer the following advantages:
- Animal Free - the proteins can be manufactured without the need for animal material and are bacterial in origin
- Low Cost- Recombinant manufacture is a scalable reproducible way of producing protein
- Ultra Stable (easy to use/ship, lower wastage)
- Ability to supply at different scales
- Can replace multiple reagents with a single material
- Can be re-used
- Easily incorporated into existing 3D materials - Technical Specification or Expertise Sought
- Partners will have a proven background in one of the target areas previous stated
- Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 15: Life on Land
- Goal 9: Industry, Innovation and Infrastructure
- Goal 3: Good Health and Well-being
- Goal 13: Climate Action
- IPR status
- IPR granted
- IPR notes
- WO2013186545A2 Recombinant Polypeptide
Partner Sought
- Expected Role of a Partner
-
The company is looking for international partners, particularly in the Netherlands, France, Denmark, and other regions, with expertise in one or more of the following fields:
• Cultivated meat
• Cell therapy
• 3D models for drug testing
The ideal partner should be a company, research institution, or biotech organisation with:
• Prior commercial experience in the target application areas.
• Technical expertise in product development, testing, or commercialisation of biomaterials for cell culture and regenerative medicine.
• Distribution networks for biotech materials or reagents.
• Access to funding and grant opportunities, particularly through hospital or university collaborations.
Expected Role of the Partner
The international partner would:
• Co-develop and test novel bioactive protein polymer materials in their application area.
• Collaborate on the development of bespoke solutions to reduce bioprocessing costs.
• Validate and provide feedback on existing and new product lines.
• Support regulatory and market entry strategies for different regions.
The partnership will be structured as a commercial agreement with technical assistance, with potential licensing opportunities available for the right collaborators. - Type and Size of Partner
- SME 11-49
- R&D Institution
- SME <=10
- SME 50 - 249
- University
- Type of partnership
- Commercial agreement
Dissemination
- Technology keywords
- 06002009 - Molecular design
- 06002004 - Protein Engineering
- 06006012 - Bioprocesses
- 06006004 - Biopolymers
- Market keywords
- 04007 - Enzymology/Protein Engineering/Fermentation
- 05008002 - Food and feed ingredients
- 04008 - Genetic Engineering
- 04006 - Cellular and Molecular Biology
- 09005 - Agriculture, Forestry, Fishing, Animal Husbandry & Related Products
- Sector Groups Involved
- Agri-Food
- Health
- Targeted countries
- All countries